Author of

• 12769

  +

  P3.18 - Poster Session 3 - Pathology (ID 177)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12777

    +

    P3.18-008 - EGFR Mutation Testing in Saudi Arabian Lung Adenocarcinoma (ID 1847)

    09:30 - 09:30  |  Author(s): P. Bavi
    • Abstract

    Background
    Lung cancer is the fifth leading cause of cancer in males in Saudi Arabia. As per current World Health Organization (WHO), lung carcinoma is subdivided into small cell and non-small cell carcinoma (NSCLC). The latter compromise 70-80% of lung carcinoma and consists of heterogenous groups that is further divided into adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Due to poor prognosis of lung cancer, there is an increasing need to find molecular biomarkers which can be used for diagnosis, risk stratification, early detection, treatment selection, prognosis and monitoring for recurrence. Increasing interest in adenocarcinoma of lung has been raised lately for various reasons. One reason is the increasing incidence of adenocarcinoma, which is now the most predominant histologic subtype. Other reason is the possible use of targeted therapy in cases showing EGFR mutations or ALK rearrangements. Adenocarcinoma comprise approximately 70% of primary lung cancer in Saudi population. The aim of this study is to review the incidence of EGFR mutation in lung adenocarcinoma in Saudi patients.

    Methods
    A cohort of 37 primary lung adenocarcinoma diagnosed histologically and confirmed by Immunohistochemistry was collected. DNA was manually extracted from paraffin embedded tissue and was paired with histology-guided tissue macrodissection to target tumor cells. The mutation status of EGFR exons 18-21 was evaluated using Polymerase chain reaction (PCR) and bi-directional sequencing.

    Results
    EGFR mutation was detected in 10 cases (27%). Of the 10 cases, 80% of mutations (deletions) were located in exon 19 and 10% in exons 20 and 21 respectively. All mutations detected conferred increased sensitivity to tyrosine kinase inhibitors (TKI).

    Conclusion
    The incidence of EGFR mutation in lung adenocarcinoma in our patients (27%) is slightly higher than western population (15-23%). To our knowledge, this is the first molecular analysis of EGFR gene mutational analysis in lung adenocarcinoma in Saudi Arabia.